Drug Combination Studies of Isoquinolinone AM12 with Curcumin or Quercetin: A New Combination Strategy to Synergistically Inhibit 20S Proteasome
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Amm, I.; Sommer, T.; Wolf, D.H. Protein quality control and elimination of protein waste: The role of the ubiquitin–proteasome system. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2014, 1843, 182–196. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Li, S.; Wu, H. Ubiquitination-Proteasome System (UPS) and Autophagy Two Main Protein Degradation Machineries in Response to Cell Stress. Cells 2022, 11, 851. [Google Scholar] [CrossRef] [PubMed]
- DeMartino, G.N.; Gillette, T.G. Proteasomes: Machines for All Reasons. Cell 2007, 129, 659–662. [Google Scholar] [CrossRef] [PubMed]
- Lecker, S.H.; Goldberg, A.L.; Mitch, W.E. Protein Degradation by the Ubiquitin–Proteasome Pathway in Normal and Disease States. J. Am. Soc. Nephrol. 2006, 17, 1807–1819. [Google Scholar] [CrossRef] [PubMed]
- Bard, J.A.; Goodall, E.A.; Greene, E.R.; Jonsson, E.; Dong, K.C.; Martin, A. Structure and Function of the 26S Proteasome. Annu. Rev. Biochem. 2018, 87, 697–724. [Google Scholar] [CrossRef]
- Livneh, I.; Cohen-Kaplan, V.; Cohen-Rosenzweig, C.; Avni, N.; Ciechanover, A. The life cycle of the 26S proteasome: From birth, through regulation and function, and onto its death. Cell Res. 2016, 26, 869–885. [Google Scholar] [CrossRef]
- Kunjappu, M.J.; Hochstrasser, M. Assembly of the 20S proteasome. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2014, 1843, 2–12. [Google Scholar] [CrossRef]
- Saha, A.; Oanca, G.; Mondal, D.; Warshel, A. Exploring the Proteolysis Mechanism of the Proteasomes. J. Phys. Chem. B 2020, 124, 5626–5635. [Google Scholar] [CrossRef]
- Park, J.; Cho, J.; Song, E.J. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment. Arch. Pharmacal Res. 2020, 43, 1144–1161. [Google Scholar] [CrossRef]
- Di Costanzo, A.; Del Gaudio, N.; Conte, L.; Altucci, L. The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options. Cancers 2020, 12, 1898. [Google Scholar] [CrossRef]
- Parlati, F.; Lee, S.J.; Aujay, M.; Suzuki, E.; Levitsky, K.; Lorens, J.B.; Micklem, D.R.; Ruurs, P.; Sylvain, C.; Lu, Y.; et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114, 3439–3447. [Google Scholar] [CrossRef] [PubMed]
- Kane, R.C.; Bross, P.F.; Farrell, A.T.; Pazdur, R. Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapy. Oncologist 2003, 8, 508–513. [Google Scholar] [CrossRef] [PubMed]
- Zhang, D.; Yang, G.; Zhang, L.; Wu, M.; Su, R. The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment. Recent Pat. Anti-Cancer Drug Discov. 2022, 17, 268–283. [Google Scholar] [CrossRef] [PubMed]
- Huang, Z.; Wu, Y.; Zhou, X.; Xu, J.; Zhu, W.; Shu, Y.; Liu, P. Efficacy of Therapy with Bortezomib in Solid Tumors: A Review based on 32 Clinical Trials. Future Oncol. 2014, 10, 1795–1807. [Google Scholar] [CrossRef] [PubMed]
- Huang, I.-T.; Dhungel, B.; Shrestha, R.; Bridle, K.R.; Crawford, D.H.G.; Jayachandran, A.; Steel, J.C. Spotlight on Bortezomib: Potential in the treatment of hepatocellular carcinoma. Expert Opin. Investig. Drugs 2018, 28, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Alwahsh, M.; Farhat, J.; Talhouni, S.; Hamadneh, L.; Hergenroeder, R. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications. EXCLI J. 2023, 22, 146–168. [Google Scholar] [CrossRef] [PubMed]
- Meregalli, C.; Maricich, Y.; Cavaletti, G.; Canta, A.; Carozzi, V.A.; Chiorazzi, A.; Newbold, E.; Marmiroli, P.; Ceresa, C.; Diani, A.; et al. Reversal of Bortezomib-Induced Neurotoxicity by Suvecaltamide, a Selective T-Type Ca-Channel Modulator, in Preclinical Models. Cancers 2021, 13, 5013. [Google Scholar] [CrossRef]
- Ettari, R.; Iraci, N.; Di Chio, C.; Previti, S.; Danzè, M.; Zappalà, M. Development of isoquinolinone derivatives as immunoproteasome inhibitors. Bioorg. Med. Chem. Lett. 2021, 55, 128478. [Google Scholar] [CrossRef]
- Ettari, R.; Cerchia, C.; Maiorana, S.; Guccione, M.; Novellino, E.; Bitto, A.; Grasso, S.; Lavecchia, A.; Zappalà, M. Development of Novel Amides as Noncovalent Inhibitors of Immunoproteasomes. ChemMedChem 2019, 14, 842–852. [Google Scholar] [CrossRef]
- Maccari, R.; Ettari, R.; Adornato, I.; Naß, A.; Wolber, G.; Bitto, A.; Mannino, F.; Aliquò, F.; Bruno, G.; Nicolò, F.; et al. Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors. Bioorg. Med. Chem. Lett. 2018, 28, 278–283. [Google Scholar] [CrossRef]
- Di Giovanni, C.; Ettari, R.; Sarno, S.; Rotondo, A.; Bitto, A.; Squadrito, F.; Altavilla, D.; Schirmeister, T.; Novellino, E.; Grasso, S.; et al. Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening. Eur. J. Med. Chem. 2016, 121, 578–591. [Google Scholar] [CrossRef] [PubMed]
- Troiano, V.; Scarbaci, K.; Ettari, R.; Micale, N.; Cerchia, C.; Pinto, A.; Schirmeister, T.; Novellino, E.; Grasso, S.; Lavecchia, A.; et al. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Eur. J. Med. Chem. 2014, 83, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Scarbaci, K.; Troiano, V.; Ettari, R.; Pinto, A.; Micale, N.; Di Giovanni, C.; Cerchia, C.; Schirmeister, T.; Novellino, E.; Lavecchia, A.; et al. Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents. ChemMedChem 2014, 9, 1801–1816. [Google Scholar] [CrossRef] [PubMed]
- Scarbaci, K.; Troiano, V.; Micale, N.; Ettari, R.; Tamborini, L.; Di Giovanni, C.; Cerchia, C.; Grasso, S.; Novellino, E.; Schirmeister, T.; et al. Identification of a new series of amides as non-covalent proteasome inhibitors. Eur. J. Med. Chem. 2014, 76, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Carrizzo, A.; Moltedo, O.; Damato, A.; Martinello, K.; Di Pietro, P.; Oliveti, M.; Acernese, F.; Giugliano, G.; Izzo, R.; Sommella, E.; et al. New Nutraceutical Combination Reduces Blood Pressure and Improves Exercise Capacity in Hypertensive Patients Via a Nitric Oxide-Dependent Mechanism. J. Am. Heart Assoc. 2020, 9, e014923. [Google Scholar] [CrossRef]
- Rahimifard, M.; Baeeri, M.; Mousavi, T.; Azarnezhad, A.; Haghi-Aminjan, H.; Abdollahi, M. Combination therapy of cisplatin and resveratrol to induce cellular aging in gastric cancer cells: Focusing on oxidative stress, and cell cycle arrest. Front. Pharmacol. 2023, 13, 1068863. [Google Scholar] [CrossRef]
- Zhu, H.; Cheng, H.; Ren, Y.; Liu, Z.G.; Zhang, Y.F.; De Luo, B. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo. Mol. Biol. Rep. 2011, 39, 4971–4979. [Google Scholar] [CrossRef]
- Puri, V.; Nagpal, M.; Singh, I.; Singh, M.; Dhingra, G.A.; Huanbutta, K.; Dheer, D.; Sharma, A.; Sangnim, T. A Comprehensive Review on Nutraceuticals: Therapy Support and Formulation Challenges. Nutrients 2022, 14, 4637. [Google Scholar] [CrossRef]
- Chan, Y.-P.; Chuang, C.-H.; Lee, I.; Yang, N.-C. Lycopene in Combination With Sorafenib Additively Inhibits Tumor Metastasis in Mice Xenografted With Lewis Lung Carcinoma Cells. Front. Nutr. 2022, 9, 886988. [Google Scholar] [CrossRef]
- Ding, K.; Jiang, W.; Jia, H.; Lei, M. Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib. Biomolecules 2022, 12, 1647. [Google Scholar] [CrossRef]
- Foucquier, J.; Guedj, M. Analysis of drug combinations: Current methodological landscape. Pharmacol. Res. Perspect. 2015, 3, e00149. [Google Scholar] [CrossRef] [PubMed]
- Pourkavoos, N. Unique Risks, Benefits, and Challenges of Developing Drug-Drug Combination Products in a Pharmaceutical Industrial Setting. Comb. Prod. Ther. 2012, 2, 2. [Google Scholar] [CrossRef]
- Di Chio, C.; Previti, S.; Totaro, N.; De Luca, F.; Allegra, A.; Schirmeister, T.; Zappalà, M.; Ettari, R. Dipeptide Nitrile CD34 with Curcumin: A New Improved Combination Strategy to Synergistically Inhibit Rhodesain of Trypanosoma brucei rhodesiense. Int. J. Mol. Sci. 2023, 24, 8477. [Google Scholar] [CrossRef] [PubMed]
- Di Chio, C.; Previti, S.; De Luca, F.; Bogacz, M.; Zimmer, C.; Wagner, A.; Schirmeister, T.; Zappalà, M.; Ettari, R. Drug Combination Studies of the Dipeptide Nitrile CD24 with Curcumin: A New Strategy to Synergistically Inhibit Rhodesain of Trypanosoma brucei rhodesiense. Int. J. Mol. Sci. 2022, 23, 14470. [Google Scholar] [CrossRef]
- Ettari, R.; Previti, S.; Di Chio, C.; Maiorana, S.; Allegra, A.; Schirmeister, T.; Zappalà, M. Drug Synergism: Studies of Combination of RK-52 and Curcumin against Rhodesain of Trypanosoma brucei rhodesiense. ACS Med. Chem. Lett. 2020, 11, 806–810. [Google Scholar] [CrossRef]
- Ettari, R.; Previti, S.; Maiorana, S.; Allegra, A.; Schirmeister, T.; Grasso, S.; Zappalà, M. Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense. Nat. Prod. Res. 2018, 33, 3577–3581. [Google Scholar] [CrossRef]
- Chou, T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70, 440–446. [Google Scholar] [CrossRef]
- Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Regul. 1984, 22, 27–55. [Google Scholar] [CrossRef]
- Hewlings, S.J.; Kalman, D.S. Curcumin: A Review of Its Effects on Human Health. Foods 2017, 6, 92. [Google Scholar] [CrossRef]
- Fuloria, S.; Mehta, J.; Chandel, A.; Sekar, M.; Rani, N.N.I.M.; Begum, M.Y.; Subramaniyan, V.; Chidambaram, K.; Thangavelu, L.; Nordin, R.; et al. A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin. Front. Pharmacol. 2022, 13, 820806. [Google Scholar] [CrossRef]
- Kunnumakkara, A.B.; Bordoloi, D.; Padmavathi, G.; Monisha, J.; Roy, N.K.; Prasad, S.; Aggarwal, B.B. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br. J. Pharmacol. 2017, 174, 1325–1348. [Google Scholar] [CrossRef] [PubMed]
- Bordoloi, D.; Roy, N.K.; Monisha, J.; Padmavathi, G.; Kunnumakkara, A.B. Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far. Recent Pat. Anti-Cancer Drug Discov. 2016, 11, 67–97. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, S.; Ji, C.; Mayfield, J.E.; Goel, A.; Xiao, J.; Dixon, J.E.; Guo, X. Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2. Proc. Natl. Acad. Sci. USA 2018, 115, 8155–8160. [Google Scholar] [CrossRef] [PubMed]
- Milacic, V.; Banerjee, S.; Landis-Piwowar, K.R.; Sarkar, F.H.; Majumdar, A.P.N.; Dou, Q.P. Curcumin Inhibits the Proteasome Activity in Human Colon Cancer Cells In vitro and In vivo. Cancer Res. 2008, 68, 7283–7292. [Google Scholar] [CrossRef] [PubMed]
- Liu, L.; Fu, Y.; Zheng, Y.; Ma, M.; Wang, C. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis. Phytomedicine 2020, 78, 153312. [Google Scholar] [CrossRef]
- Tabanelli, R.; Brogi, S.; Calderone, V. Improving Curcumin Bioavailability: Current Strategies and Future Perspectives. Pharmaceutics 2021, 13, 1715. [Google Scholar] [CrossRef]
- Bertoncini-Silva, C.; Vlad, A.; Ricciarelli, R.; Fassini, P.G.; Suen, V.M.M.; Zingg, J.-M. Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment. Antioxidants 2024, 13, 331. [Google Scholar] [CrossRef]
- Vollmannová, A.; Bojňanská, T.; Musilová, J.; Lidiková, J.; Cifrová, M. Quercetin as one of the most abundant represented biological valuable plant components with remarkable chemoprotective effects—A review. Heliyon 2024, 10, e33342. [Google Scholar] [CrossRef]
- Aghababaei, F.; Hadidi, M. Recent Advances in Potential Health Benefits of Quercetin. Pharmaceuticals 2023, 16, 1020. [Google Scholar] [CrossRef]
- Rauf, A.; Imran, M.; Khan, I.A.; Ur-Rehman, M.; Gilani, S.A.; Mehmood, Z.; Mubarak, M.S. Anticancer potential of quercetin: A comprehensive review. Phytother. Res. 2018, 32, 2109–2130. [Google Scholar] [CrossRef]
- Mirza, M.A.; Mahmood, S.; Hilles, A.R.; Ali, A.; Khan, M.Z.; Zaidi, S.A.A.; Iqbal, Z.; Ge, Y. Quercetin as a Therapeutic Product: Evaluation of Its Pharmacological Action and Clinical Applications—A Review. Pharmaceuticals 2023, 16, 1631. [Google Scholar] [CrossRef] [PubMed]
- Chang, T.-L. Inhibitory Effect of Flavonoids on 26S Proteasome Activity. J. Agric. Food Chem. 2009, 57, 9706–9715. [Google Scholar] [CrossRef] [PubMed]
- Chang, T.-L.; Wang, C.-H. Combination of quercetin and tannic acid in inhibiting 26S proteasome affects S5a and 20S expression, and accumulation of ubiquitin resulted in apoptosis in cancer chemoprevention. Biol. Chem. 2013, 394, 561–575. [Google Scholar] [CrossRef] [PubMed]
- Duarte, D.; Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 2022, 3, 100110. [Google Scholar] [CrossRef] [PubMed]
Compound | 0.062 × IC50 | 0.25 × IC50 | 0.5 × IC50 | IC50 | 2 × IC50 | 4 × IC50 |
---|---|---|---|---|---|---|
Curcumin | 0.15 µM | 0.61 µM | 1.23 µM | 2.46 µM | 4.92 µM | 9.84 µM |
AM12 | 0.76 µM | 3.04 µM | 6.08 µM | 12.17 µM | 24.34 µM | 48.68 µM |
Curcumin + AM12 | 0.15 + 0.76 µM | 0.61 + 3.04 µM | 1.23 + 6.08 µM | 2.46 + 12.17 µM | 4.92 + 24.34 µM | 9.84 + 48.68 µM |
Compound | 0.062 × IC50 | 0.25 × IC50 | 0.5 × IC50 | IC50 | 2 × IC50 | 4 × IC50 |
---|---|---|---|---|---|---|
Quercetin | 0.19 µM | 0.74 µM | 1.48 µM | 2.96 µM | 5.92 µM | 11.84 µM |
AM12 | 0.76 µM | 3.04 µM | 6.08 µM | 12.17 µM | 24.34 µM | 48.68 µM |
Quercetin + AM12 | 0.19 + 0.76 µM | 0.74 + 3.04 µM | 1.48 + 6.08 µM | 2.96 + 12.17 µM | 5.92 + 24.34 µM | 11.84 + 48.68 µM |
Inhibited Fraction (fa) | % β5 Subunit Inhibition | Combination | CI | Effect | Combination | CI | Effect |
---|---|---|---|---|---|---|---|
0.50 | 50% | AM12 + Curcumin | 0.71 | Synergism | AM12 + Quercetin | 1.04 | Additive effect |
0.60 | 60% | AM12 + Curcumin | 0.60 | Synergism | AM12 + Quercetin | 1.03 | Additive effect |
0.70 | 70% | AM12 + Curcumin | 0.50 | Synergism | AM12 + Quercetin | 1.04 | Additive effect |
0.80 | 80% | AM12 + Curcumin | 0.43 | Synergism | AM12 + Quercetin | 1.11 | Slight antagonism |
0.90 | 90% | AM12 + Curcumin | 0.38 | Synergism | AM12 + Quercetin | 1.31 | Moderate antagonism |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Chio, C.; Previti, S.; Starvaggi, J.; De Luca, F.; Calabrò, M.L.; Zappalà, M.; Ettari, R. Drug Combination Studies of Isoquinolinone AM12 with Curcumin or Quercetin: A New Combination Strategy to Synergistically Inhibit 20S Proteasome. Int. J. Mol. Sci. 2024, 25, 10708. https://doi.org/10.3390/ijms251910708
Di Chio C, Previti S, Starvaggi J, De Luca F, Calabrò ML, Zappalà M, Ettari R. Drug Combination Studies of Isoquinolinone AM12 with Curcumin or Quercetin: A New Combination Strategy to Synergistically Inhibit 20S Proteasome. International Journal of Molecular Sciences. 2024; 25(19):10708. https://doi.org/10.3390/ijms251910708
Chicago/Turabian StyleDi Chio, Carla, Santo Previti, Josè Starvaggi, Fabiola De Luca, Maria Luisa Calabrò, Maria Zappalà, and Roberta Ettari. 2024. "Drug Combination Studies of Isoquinolinone AM12 with Curcumin or Quercetin: A New Combination Strategy to Synergistically Inhibit 20S Proteasome" International Journal of Molecular Sciences 25, no. 19: 10708. https://doi.org/10.3390/ijms251910708